Abbott Laboratories seen as strong buy with 21.8–39.4% upside amid undervaluation and growth prospects.

Abbott Laboratories is rated a strong buy due to its undervaluation and solid fundamentals despite recent price drops. Trading at a significant discount to peers, the company's value is supported by growth drivers like the Exact Sciences acquisition and expansion in continuous glucose monitoring globally. Analysts have raised full-year 2026 sales and earnings guidance, with average price targets suggesting up to 39.4% upside. This outlook indicates potential for Abbott to be re-rated higher by the market.